British doctors lobby NHS to use cheap Avastin over Lucentis in AMD

Here's a new threat to Lucentis, the eye drug from Roche ($RHHBY) and Novartis ($NVS). British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis. The two drugs work in a similar fashion and some studies show they work equally well for eye problems, but Avastin isn't licensed for use in the eye. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.